Differential regulatory effects of chemotherapeutic protocol on CCL3_CCL4_CCL5/CCR5 axes in acute myeloid leukemia patients with monocytic lineage

Yazdani, Zinat; Mousavi, Zahra; Ghasemimehr, Narges; Khandany, Behjat Kalantary; Nikbakht, Roshan; Jafari, Elham; Fatemi, Ahmad; Hassanshahi, Gholamhossein

doi:10.1016/j.lfs.2019.117071

Cited by 22 publications

(9 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AML patients are classified into subsets according to their chemokine responsiveness and chemokine expression profile [89]. AML patients with the monocytic phenotype have high serum levels of CCL5, CCL4, and CCL3 [90]. After the first stage of chemotherapy in these patients, CCR5 expression decreases and CCL3 returns to baseline levels, whereas CCL5 and CCL4 only decreases [90].…”

Section: Acute Myeloid Leukemiamentioning

confidence: 99%

The CCL5/CCR5 Axis in Cancer Progression

Aldinucci

Borghese

Casagrande

2020

Cancers

285

191

View full text Add to dashboard Cite

Tumor cells can “hijack” chemokine networks to support tumor progression. In this context, the C-C chemokine ligand 5/C-C chemokine receptor type 5 (CCL5/CCR5) axis is gaining increasing attention, since abnormal expression and activity of CCL5 and its receptor CCR5 have been found in hematological malignancies and solid tumors. Numerous preclinical in vitro and in vivo studies have shown a key role of the CCL5/CCR5 axis in cancer, and thus provided the rationale for clinical trials using the repurposed drug maraviroc, a CCR5 antagonist used to treat HIV/AIDS. This review summarizes current knowledge on the role of the CCL5/CCR5 axis in cancer. First, it describes the involvement of the CCL5/CCR5 axis in cancer progression, including autocrine and paracrine tumor growth, ECM (extracellular matrix) remodeling and migration, cancer stem cell expansion, DNA damage repair, metabolic reprogramming, and angiogenesis. Then, it focuses on individual hematological and solid tumors in which CCL5 and CCR5 have been studied preclinically. Finally, it discusses clinical trials of strategies to counteract the CCL5/CCR5 axis in different cancers using maraviroc or therapeutic monoclonal antibodies.

show abstract

Section: Acute Myeloid Leukemiamentioning

confidence: 99%

The CCL5/CCR5 Axis in Cancer Progression

Aldinucci

Borghese

Casagrande

2020

Cancers

285

191

View full text Add to dashboard Cite

show abstract

“…In a previous study, we found that the serum levels of CCL3, CCL4 and CCL5 chemokines were elevated in AML patients before chemotherapy. Chemotherapy inhibited CCL3 but not CCL4 and CCL5, which could be associated with a poor prognosis in AML patients (24).…”

Section: Discussionmentioning

confidence: 95%

Effect of Chemotherapy on CXCL1 and CXCL10 Levels in Acute Myeloid Leukemia Patients with M4/M5 Subtype

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background and objectives: Acute myeloid leukemia (AML) is a heterogeneous malignancy caused by various pathological mechanisms. Chemokines are involved in the initiation, progression, migration, survival, treatment and complications of AML. CXCL1 has an indirect effect on the progression of cancer and CXCL10 produced by leukemia cells attracts natural killer cells toward tumor sites to eradicate cancer cells. The present study investigated effects of chemotherapy on serum levels of CXCL1 and CXCL10 in patients with AML.Methods: Throughout this case-control study, blood samples were collected from AML patients with M4/M5 subtype (n=25) before and after the first stage of a chemotherapy regimen (7+3). Serum levels of the chemokines were determined using commercial ELISA kits. Data were analyzed using two-sample and paired T-test in SPSS 22 software.Results: The level of CXCL10 was high in patients but decreased following chemotherapy. After the chemotherapy the patients attained partial remission. However, the level of CXCL1 did not change in the patients. Conclusion:Although chemotherapy could decrease CXCL10 levels and induce partial remission, CXCL1 levels does not change in AML patients with M4/M5 subtype. Based on the results, the employment of CXCL1 and CXCL10 inhibitors in the chemotherapy regimen could prevent relapse in the later stages or even reduce the duration of treatment.

show abstract

“…AML patients with monocytic differentiation had increased serum levels of CCL4 along with CCL5 and CCL3. The three biomarkers promote an inflammatory state and participated in the progression of suppressing T cell-related immune response ( 28 ). GZMB encodes the preprotein secreted by NK cell and CTLs, which is related to the apoptosis of target cells ( 29 ).…”

Section: Discussionmentioning

confidence: 99%

Development and Validation of a Novel Prognostic Model for Acute Myeloid Leukemia Based on Immune-Related Genes

Ding

Jin

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

The prognosis of acute myeloid leukemia (AML) is closely related to immune response changes. Further exploration of the pathobiology of AML focusing on immune-related genes would contribute to the development of more advanced evaluation and treatment strategies. In this study, we established a novel immune-17 signature based on transcriptome data from The Cancer Genome Atlas (TCGA) and The Genotype-Tissue Expression (GTEx) databases. We found that immune biology processes and transcriptional dysregulations are critical factors in the development of AML through enrichment analyses. We also formulated a prognostic model to predict the overall survival of AML patients by using LASSO (Least Absolute Shrinkage and Selection Operator) regression analysis. Furthermore, we incorporated the immune-17 signature to improve the prognostic accuracy of the ELN2017 risk stratification system. We concluded that the immune-17 signature represents a novel useful model for evaluating AML survival outcomes and may be implemented to optimize treatment selection in the next future.

show abstract

Differential regulatory effects of chemotherapeutic protocol on CCL3_CCL4_CCL5/CCR5 axes in acute myeloid leukemia patients with monocytic lineage

Cited by 22 publications

References 20 publications

The CCL5/CCR5 Axis in Cancer Progression

The CCL5/CCR5 Axis in Cancer Progression

Effect of Chemotherapy on CXCL1 and CXCL10 Levels in Acute Myeloid Leukemia Patients with M4/M5 Subtype

Development and Validation of a Novel Prognostic Model for Acute Myeloid Leukemia Based on Immune-Related Genes

Contact Info

Product

Resources

About